Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw unusually-high trading volume on Monday . Approximately 24,215 shares traded hands during trading, a decline of 16% from the previous session’s volume of 28,850 shares.The stock last traded at $8.86 and had previously closed at $8.04.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a report on Friday, September 20th.

Aligos Therapeutics Price Performance

The company has a fifty day moving average of $12.72 and a two-hundred day moving average of $15.70. The stock has a market capitalization of $688.93 million, a P/E ratio of -6.92 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. The company had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the previous year, the firm earned ($10.75) earnings per share. As a group, equities research analysts predict that Aligos Therapeutics, Inc. will post -8.2 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. bought a new stake in Aligos Therapeutics in the 4th quarter valued at $1,889,000. Opaleye Management Inc. lifted its holdings in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Aligos Therapeutics by 26.1% during the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).